Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T in European Men With mCRPC
NCT01477749Phase 2Completed
- Sponsor
- Dendreon
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Started Jun 2012; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01477749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01477749.